Concepts (82)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dideoxynucleosides | 2 | 2023 | 29 | 0.620 |
Why?
|
| Stavudine | 1 | 2017 | 78 | 0.550 |
Why?
|
| HIV Infections | 8 | 2024 | 4946 | 0.530 |
Why?
|
| HIV | 1 | 2017 | 380 | 0.470 |
Why?
|
| Anti-HIV Agents | 4 | 2024 | 1275 | 0.460 |
Why?
|
| Emtricitabine | 3 | 2024 | 74 | 0.290 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 3 | 2024 | 76 | 0.290 |
Why?
|
| Tenofovir | 3 | 2024 | 158 | 0.280 |
Why?
|
| Ritonavir | 2 | 2017 | 137 | 0.240 |
Why?
|
| Viral Load | 5 | 2023 | 808 | 0.240 |
Why?
|
| Oxazines | 2 | 2024 | 71 | 0.240 |
Why?
|
| Piperazines | 2 | 2024 | 73 | 0.240 |
Why?
|
| Pyridones | 2 | 2024 | 87 | 0.230 |
Why?
|
| Adenine | 2 | 2023 | 88 | 0.230 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2024 | 467 | 0.210 |
Why?
|
| Drug Resistance, Viral | 1 | 2024 | 268 | 0.200 |
Why?
|
| Female | 9 | 2024 | 8751 | 0.200 |
Why?
|
| Lamivudine | 2 | 2023 | 86 | 0.190 |
Why?
|
| Male | 7 | 2023 | 6489 | 0.180 |
Why?
|
| Viremia | 1 | 2019 | 66 | 0.160 |
Why?
|
| Infant | 4 | 2020 | 2145 | 0.160 |
Why?
|
| Humans | 9 | 2024 | 14077 | 0.150 |
Why?
|
| Child, Preschool | 3 | 2020 | 1675 | 0.150 |
Why?
|
| Drug Combinations | 1 | 2017 | 41 | 0.140 |
Why?
|
| HIV-1 | 3 | 2024 | 1239 | 0.140 |
Why?
|
| Streptococcus pneumoniae | 1 | 2020 | 320 | 0.140 |
Why?
|
| Treatment Outcome | 2 | 2017 | 867 | 0.140 |
Why?
|
| Lopinavir | 1 | 2017 | 137 | 0.140 |
Why?
|
| Pneumococcal Infections | 1 | 2020 | 287 | 0.140 |
Why?
|
| Influenza Vaccines | 2 | 2020 | 132 | 0.130 |
Why?
|
| Anti-Retroviral Agents | 1 | 2019 | 542 | 0.120 |
Why?
|
| Retrospective Studies | 1 | 2017 | 767 | 0.120 |
Why?
|
| Carbamates | 1 | 2014 | 12 | 0.110 |
Why?
|
| Organophosphates | 1 | 2014 | 8 | 0.110 |
Why?
|
| Sulfonamides | 1 | 2014 | 10 | 0.110 |
Why?
|
| Benzoxazines | 2 | 2024 | 119 | 0.110 |
Why?
|
| Pregnancy | 3 | 2024 | 1815 | 0.110 |
Why?
|
| Pneumonia | 1 | 2013 | 127 | 0.090 |
Why?
|
| Antibodies, Viral | 1 | 2013 | 266 | 0.090 |
Why?
|
| HIV Seropositivity | 1 | 2013 | 263 | 0.090 |
Why?
|
| South Africa | 3 | 2020 | 7312 | 0.090 |
Why?
|
| Influenza, Human | 1 | 2013 | 360 | 0.080 |
Why?
|
| Infant, Newborn | 2 | 2024 | 1410 | 0.080 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2024 | 507 | 0.070 |
Why?
|
| Adult | 3 | 2024 | 5664 | 0.070 |
Why?
|
| Prevalence | 2 | 2020 | 1149 | 0.060 |
Why?
|
| Child | 2 | 2023 | 2180 | 0.060 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2019 | 654 | 0.060 |
Why?
|
| Alkynes | 1 | 2024 | 113 | 0.060 |
Why?
|
| Cyclopropanes | 1 | 2024 | 119 | 0.060 |
Why?
|
| Tablets | 1 | 2023 | 39 | 0.050 |
Why?
|
| RNA | 1 | 2023 | 26 | 0.050 |
Why?
|
| Alanine | 1 | 2021 | 29 | 0.050 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2021 | 24 | 0.050 |
Why?
|
| Gestational Age | 1 | 2021 | 78 | 0.050 |
Why?
|
| Pregnancy Outcome | 1 | 2021 | 112 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 271 | 0.040 |
Why?
|
| Nasal Lavage Fluid | 1 | 2020 | 2 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2020 | 45 | 0.040 |
Why?
|
| Self Report | 1 | 2019 | 111 | 0.040 |
Why?
|
| Africa South of the Sahara | 1 | 2019 | 328 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 409 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 405 | 0.040 |
Why?
|
| Risk Factors | 1 | 2019 | 1431 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 1377 | 0.030 |
Why?
|
| Furans | 1 | 2014 | 4 | 0.030 |
Why?
|
| HIV Protease Inhibitors | 1 | 2014 | 92 | 0.030 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 2013 | 23 | 0.030 |
Why?
|
| Virus Shedding | 1 | 2013 | 24 | 0.030 |
Why?
|
| Young Adult | 1 | 2019 | 2357 | 0.030 |
Why?
|
| Influenza A virus | 1 | 2013 | 28 | 0.030 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2013 | 31 | 0.030 |
Why?
|
| Influenza B virus | 1 | 2013 | 42 | 0.030 |
Why?
|
| Adolescent | 1 | 2020 | 2858 | 0.030 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2013 | 54 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2014 | 303 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2013 | 263 | 0.030 |
Why?
|
| Phylogeny | 1 | 2013 | 231 | 0.020 |
Why?
|
| Middle Aged | 1 | 2019 | 3425 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 367 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2014 | 939 | 0.020 |
Why?
|
| Hospitalization | 1 | 2013 | 392 | 0.020 |
Why?
|